Follow

Intervju med VD för Idogen inför nyemission

17 February 2020 - 13:34
Intervju med Anders Karlsson, VD för Idogen, inför att bolaget gör en nyemission....
Nasdaq First North Sweden (Sweden)
Idogen AB
Idogen AB is a Swedish biotech company engaged in developing tolerogenic cell therapies to prevent biological drugs, transplanted or body cells or tissues from being attacked by the patient's immune system. Its product IDO 8, treats patients with severe hemorrhagic disease....
Learn more about company

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date